BackProvention Bio Overview

Provention Bio Long Term Debt

Track Provention Bio's long-term debt ($24M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$23.91M
3952.54% YoYΔ $23.32M vs prior year quarter

Peer average

Loading

Provention Bio Long Term Debt History

Loading

Provention Bio vs. peers: Long Term Debt Comparison

Loading

Provention Bio Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Provention Bio (PRVB) FAQ

As of the most recent data (December 2022), PRVB shows a long-term debt of $24M. That compares with $590K in the prior-year period — up 3952.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PRVB's long-term debt is now $24M (was $590K) — a 3952.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Provention Bio is outperforming or lagging.

Tracking PRVB's long-term debt over time shows whether Provention Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $24M That compares with $590K in the prior-year period — up 3952.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Provention Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $24M) with ownership activity and broader fundamentals.

Provention Bio's long-term debt is $24M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.